We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $164M
1-Year Est. Return 542.31%
This Fund
S&P 500
This Quarter Est. Return
+20.24%
1 Year Est. Return
+542.31%
3 Year Est. Return
+2,395.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$160M
AUM Growth
-$12.7M
Cap. Flow
-$13.9M
Cap. Flow %
-8.71%
Top 10 Hldgs %
73.06%
Holding
57
New
11
Increased
13
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$6.76M
2
IMMX icon
Immix Biopharma
IMMX
+$5.18M
3
AVR
Anteris Technologies
AVR
+$4.02M
4
STRO icon
Sutro Biopharma
STRO
+$3.62M
5
XNCR icon
Xencor
XNCR
+$3.1M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$23.9M
2
LNTH icon
Lantheus
LNTH
+$4.97M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$4.11M
4
RAPT
RAPT Therapeutics
RAPT
+$3.66M
5
TERN
Terns Pharmaceuticals
TERN
+$2.83M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSRX
26
Nasus Pharma
NSRX
$48M
$798K 0.5%
+359,390
New +$1.86M
QNRX
27
Quoin Pharmaceuticals
QNRX
$12.3M
$560K 0.35%
+84,849
New +$769K
ARWR icon
28
Arrowhead Research
ARWR
$12B
$408K 0.26%
6,500
– –
PTGX icon
29
Protagonist Therapeutics
PTGX
$9.34B
$390K 0.24%
3,700
– –
OVID icon
30
Ovid Therapeutics
OVID
$547M
$355K 0.22%
160,000
– –
MLYS icon
31
Mineralys Therapeutics
MLYS
$2.26B
$298K 0.19%
11,000
-140,000
-93% -$4.11M
CNTX icon
32
Context Therapeutics
CNTX
$35.3M
$262K 0.16%
100,000
– –
NRIX icon
33
Nurix Therapeutics
NRIX
$2.72B
$248K 0.16%
16,000
– –
CRBP icon
34
Corbus Pharmaceuticals
CRBP
$211M
$244K 0.15%
26,000
+13,000
+100% +$109K
SNDX icon
35
Syndax Pharmaceuticals
SNDX
$1.74B
$234K 0.15%
10,000
-120,000
-92% -$2.61M
DTIL icon
36
Precision BioSciences
DTIL
$215M
$220K 0.14%
40,000
+20,000
+100% +$92.3K
IMNM icon
37
Immunome
IMNM
$3.13B
$219K 0.14%
10,000
– –
DSGN icon
38
Design Therapeutics
DSGN
$946M
$213K 0.13%
20,000
– –
ARTV
39
Artiva Biotherapeutics
ARTV
$542M
$161K 0.1%
+25,000
New +$124K
NMRA icon
40
Neumora Therapeutics
NMRA
$261M
$156K 0.1%
+80,000
New +$207K
REPL icon
41
Replimune Group
REPL
$1.46B
$153K 0.1%
20,000
+5,000
+33% +$38.2K
LRMR icon
42
Larimar Therapeutics
LRMR
$417M
$149K 0.09%
33,000
– –
XLO icon
43
Xilio Therapeutics
XLO
$59.2M
$120K 0.08%
14,285
+2,142
+18% +$17.5K
KLRS
44
Kalaris Therapeutics
KLRS
$95.9M
$104K 0.07%
+18,000
New +$160K
PMVP icon
45
PMV Pharmaceuticals
PMVP
$65.2M
$90.5K 0.06%
73,000
+38,000
+109% +$48.3K
MGNX icon
46
MacroGenics
MGNX
$263M
$86.7K 0.05%
+30,000
New +$64K
KPTI icon
47
Karyopharm Therapeutics
KPTI
$42.4M
$83.5K 0.05%
+15,000
New +$114K
PRQR icon
48
ProQR Therapeutics
PRQR
$323M
$72.9K 0.05%
45,000
– –
GOSS icon
49
Gossamer Bio
GOSS
$83.2M
$23K 0.01%
70,000
– –
CDTX
50
DELISTED
Cidara Therapeutics
CDTX
– –
-108,404
Closed -$23.9M
1
2
3

Similar funds

WCM
Winebrenner Capital Management Louisville, Kentucky $164M AUM 12.81% 1-Year Est. Return
HWM
Hemming & Wealth Management Traverse City, Michigan $164M AUM
PSIWM
Paradigm Strategies in Wealth Management Maple Grove, Minnesota $164M AUM 18.07% 1-Year Est. Return
JWM
JDH Wealth Management Santa Rosa, California $164M AUM 28.4% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
IFA
Interactive Financial Advisors New Lenox, Illinois $164M AUM 18.28% 1-Year Est. Return
SC
Simcoe Capital Spokane, Washington $164M AUM
FLFS
Family Legacy Financial Solutions Cary, North Carolina $164M AUM 62.92% 1-Year Est. Return

Velan Capital Investment Management's Q1 2026 Portfolio in Review

As of Q1 2026, Velan Capital Investment Management held 57 positions worth $160M, down 7.4% from $172M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Velan Capital Investment Management withdrew a net $13.9M in Q1 2026, closing 8 positions and reducing 7 holdings. Its most notable exit was Cidara Therapeutics, an estimated $23.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Velan Capital Investment Management opened a new position in Anteris Technologies worth $3.88M.

  • Velan Capital Investment Management's largest Q1 2026 buy was Anteris Technologies: 700,000 shares worth $3.88M.
  • Velan Capital Investment Management added most to Tenax Therapeutics in Q1 2026, an estimated $6.76M increase.
  • Velan Capital Investment Management's biggest Q1 2026 reduction was Mineralys Therapeutics, cutting an estimated $4.11M.
  • Velan Capital Investment Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $23.9M.
  • Velan Capital Investment Management's ten largest holdings make up 73% of its $160M portfolio in Q1 2026.
  • Velan Capital Investment Management opened 11 new positions and closed 8 in Q1 2026.
  • Velan Capital Investment Management's portfolio value fell 7.4% quarter-over-quarter to $160M.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.